Stockscreener 앱 받기
29.01
1.42%
0.405
시간 외 거래:
28.91
-0.10
-0.34%
전일 마감가:
$28.61
열려 있는:
$28.6129
하루 거래량:
25,004
Relative Volume:
2.06
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.69%
1개월 성능:
-5.75%
6개월 성능:
-13.27%
1년 성능:
-12.12%
1일 변동 폭
$28.61
$29.01
1주일 범위
$28.51
$29.65
52주 변동 폭
$28.51
$36.03
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile
명칭
Tema Etf Trust Tema Obesity Cardiometabolic Etf
전화
-
주소
-
HRTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HRTS
Tema Etf Trust Tema Obesity Cardiometabolic Etf
|
29.01 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
277.95 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
564.52 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
567.20 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
226.03 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
476.15 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Etf Trust Tema Obesity Cardiometabolic Etf 주식(HRTS)의 최신 뉴스
Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Declines By 28.6% - Defense World
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Short Interest Down 60.0% in February - Defense World
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends - ETF Trends
Reshoring ETF Gets Boost From Trump Trade - etf.com
Tema's New VOLT ETF Sparked by AI Revolution - etf.com
Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Yahoo Finance
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
Tap the Weight-Loss Drug Market With These ETFs - Nasdaq
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Markets Insider
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg.com
Weight-loss drug forecasts jump to $150 billion as supply grows - The Business Standard
Watch Looking at Next Gen of Weight Loss: Tema ETFs CEO - Bloomberg
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
The 5 Best Biotech ETFs of 2024 - etf.com
Webcast: How to Invest in the Weight Loss Drug Revolution - ETF Trends
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
Be Thankful — It Could Have Been So Much Worse - Bloomberg
Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS) 재무 분석
Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.55%
자본화:
|
볼륨(24시간):